Results 151 to 160 of about 1,207,344 (315)

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin   +11 more
wiley   +1 more source

The Tale of the Residual Tail: Insights From Continuous Intracranial Monitoring From Post‐Hippocampectomy Dynamics

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Subtotal hippocampal resection can leave residual hippocampal tissue, yet the immediate postoperative electrophysiologic evolution of such remnants is unknown. We describe a patient with drug‐resistant temporal lobe epilepsy in whom a hippocampal remnant was continuously monitored using a responsive neurostimulator (RNS) following subtotal ...
Patrick Hartnett   +5 more
wiley   +1 more source

If Supply-Oriented Drug Policy is Broken, Can Harm Reduction Help Fix It?—Melding Disciplines and Methods to Advance International Drug Control Policy [PDF]

open access: yes
Critics of the international drug control regime contend that supply-oriented policy interventions are not just ineffective, but they also produce unintended adverse consequences. Research suggests their claims have merit.
Victoria A. Greenfield, Letizia Paoli
core  

Supply-side reduction policy and drug-related harm [PDF]

open access: yes, 2014
Large-scale seizures of cocaine, heroin and amphetamine-type substances (ATS) do not result in any reduction in overdoses on these drugs or on arrests for use and possession of these drugs, according to this report.
Grant Sara   +4 more
core  

CAR T‐Cell Therapy in Neurology: A Scoping Review of Neuro‐Oncology, Autoimmune Diseases & Neurotoxicity

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi   +5 more
wiley   +1 more source

If Drug Treatment Works So Well, Why Are So Many Drug Users in Prison? [PDF]

open access: yes
This paper examines the effectiveness of drug courts to reduce the size of the incarcerated drug-offending population using data from the Survey of Inmates in State Correctional Facilities and the Survey of Inmates in Local Jails.
Harold Pollack   +2 more
core  

Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC 
(2022 Version)

open access: yesChinese Journal of Lung Cancer, 2022
Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee   +1 more
doaj   +1 more source

Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (September 2021). [PDF]

open access: yesAcute Med Surg, 2021
Yamakawa K   +22 more
europepmc   +1 more source

Recurrent Hypothermia and Autonomic Dysfunction Secondary to Shapiro Syndrome

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT A 44‐year‐old man presented with recurrent hypothermia, diaphoresis and hypertension. Extensive investigation for infectious, inflammatory, metabolic and endocrine aetiologies was negative. MR scan of the brain demonstrated no lesions but revealed callosal dysgenesis, consistent with Shapiro syndrome.
Naveen Kumar   +3 more
wiley   +1 more source

Cross-organ multi-omics profiling of microbiome and metabolome along the gut–liver axis in MASH model mice induced by western diet and MC4R knockout

open access: yesGut Pathogens
Background Western diet (WD) fed Melanocortin 4 receptor-knockout (MC4R-KO) mice develop a phenotype resembling human metabolic dysfunction-associated steatohepatitis (MASH).
Mitsuharu Matsumoto   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy